Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi
Introduction: Salmonella enterica serovar Typhi is the causative agent of typhoid fever with over 22 million cases and over 200,000 deaths reported annually. A vaccine is much needed for use in young children and the Novartis Vaccines Institute for Global Health (NVGH) is developing a conjugate v...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2012-11-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/2495 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849323548366077952 |
|---|---|
| author | Simona Rondini Francesca Micoli Luisa Lanzilao Ivan Pisoni Vito Di Cioccio Allan J Saul Laura B Martin |
| author_facet | Simona Rondini Francesca Micoli Luisa Lanzilao Ivan Pisoni Vito Di Cioccio Allan J Saul Laura B Martin |
| author_sort | Simona Rondini |
| collection | DOAJ |
| description |
Introduction: Salmonella enterica serovar Typhi is the causative agent of typhoid fever with over 22 million cases and over 200,000 deaths reported annually. A vaccine is much needed for use in young children and the Novartis Vaccines Institute for Global Health (NVGH) is developing a conjugate vaccine which targets S. Typhi Vi capsular polysaccharide.
Methodology: Here we describe a method suitable for industrial scale production of the Vi antigen based on expression by a Citrobacter line. We optimized the production of Vi by selecting a suitable Citrobacter strain (Citrobacter 328) that yields high and stable expression of Vi in chemically defined medium under industrial-scale fermentation conditions.
Results: Vi-CRM197 made using Vi from Citrobacter 328 elicited high anti-Vi antibody levels in mice and rabbits.
Conclusions: Citrobacter 328 is a suitable strain for production of Vi for conjugate anti-Typhi vaccines. Being a BSL-1 organism, which grows in defined medium and stably produces high yields of Vi, it offers excellent potential for safe production of inexpensive vaccines for populations at risk of typhoid fever. |
| format | Article |
| id | doaj-art-84991e4f7efa48d5814fe0e9bce3d947 |
| institution | Kabale University |
| issn | 1972-2680 |
| language | English |
| publishDate | 2012-11-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-84991e4f7efa48d5814fe0e9bce3d9472025-08-20T03:48:58ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802012-11-0161110.3855/jidc.2495Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella TyphiSimona Rondini0Francesca Micoli1Luisa Lanzilao2Ivan Pisoni3Vito Di Cioccio4Allan J Saul5Laura B Martin6Novartis Vaccines Institute for Global HealthNovartis Vaccines Institute for Global HealthNovartis Vaccines Institute for Global HealthNovartis Vaccines Institute for Global HealthNovartis Vaccines Institute for Global HealthNovartis Vaccines Institute for Global HealthNovartis Vaccines Institute for Global Health Introduction: Salmonella enterica serovar Typhi is the causative agent of typhoid fever with over 22 million cases and over 200,000 deaths reported annually. A vaccine is much needed for use in young children and the Novartis Vaccines Institute for Global Health (NVGH) is developing a conjugate vaccine which targets S. Typhi Vi capsular polysaccharide. Methodology: Here we describe a method suitable for industrial scale production of the Vi antigen based on expression by a Citrobacter line. We optimized the production of Vi by selecting a suitable Citrobacter strain (Citrobacter 328) that yields high and stable expression of Vi in chemically defined medium under industrial-scale fermentation conditions. Results: Vi-CRM197 made using Vi from Citrobacter 328 elicited high anti-Vi antibody levels in mice and rabbits. Conclusions: Citrobacter 328 is a suitable strain for production of Vi for conjugate anti-Typhi vaccines. Being a BSL-1 organism, which grows in defined medium and stably produces high yields of Vi, it offers excellent potential for safe production of inexpensive vaccines for populations at risk of typhoid fever.https://jidc.org/index.php/journal/article/view/2495S. TyphiViCitrobacterconjugate vaccineVi-CRM197 |
| spellingShingle | Simona Rondini Francesca Micoli Luisa Lanzilao Ivan Pisoni Vito Di Cioccio Allan J Saul Laura B Martin Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi Journal of Infection in Developing Countries S. Typhi Vi Citrobacter conjugate vaccine Vi-CRM197 |
| title | Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi |
| title_full | Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi |
| title_fullStr | Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi |
| title_full_unstemmed | Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi |
| title_short | Characterization of Citrobacter sp. line 328 as a source of Vi for a Vi-CRM197 glycoconjugate vaccine against Salmonella Typhi |
| title_sort | characterization of citrobacter sp line 328 as a source of vi for a vi crm197 glycoconjugate vaccine against salmonella typhi |
| topic | S. Typhi Vi Citrobacter conjugate vaccine Vi-CRM197 |
| url | https://jidc.org/index.php/journal/article/view/2495 |
| work_keys_str_mv | AT simonarondini characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi AT francescamicoli characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi AT luisalanzilao characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi AT ivanpisoni characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi AT vitodicioccio characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi AT allanjsaul characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi AT laurabmartin characterizationofcitrobacterspline328asasourceofviforavicrm197glycoconjugatevaccineagainstsalmonellatyphi |